Get the Stockscreener App
1,133.00
2.41%
-27.95
After Hours:
1135.08
2.08
+0.18%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,133.00, with a volume of 2.43M.
It is down -2.41% in the last 24 hours and up +14.46% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,160.95
Open:
$1165
24h Volume:
2.43M
Relative Volume:
0.78
Market Cap:
$1.01T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
40.78
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+0.14%
1M Performance:
+14.46%
6M Performance:
+10.27%
1Y Performance:
+39.53%
1-Day Range:
$1,132.81
$1,169.99
1-Week Range:
$1,125.64
$1,182.73
52-Week Range:
$623.78
$1,182.73
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,133.00 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
240.87 | 573.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.73 | 397.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.05 | 298.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.07 | 293.69B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Is Eli Lilly's Growth Story Still Gaining Strength? - Kalkine Media
Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth - Yahoo Finance
The Catch Hiding In Eli Lilly Stock’s Growth Story - Trefis
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About - The Motley Fool
Eli Lilly (LLY) Moves to Enforce 340B Claims Data Reporting Compliance - Yahoo Finance
Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy - 24/7 Wall St.
Prometheus raises $12 billion in capital for artificial engineers - statnews.com
Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline - Insider Monkey
Eli Lilly and Company $LLY is Xponance LLC's 10th Largest Position - MarketBeat
American Express, Live Nation And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Eli Lilly donates $50,000 to Kenosha YMCA for teen services - Kenosha News
Polen Capital Management LLC Lowers Position in Eli Lilly and Company $LLY - MarketBeat
Kovack Advisors Inc. Purchases 3,506 Shares of Eli Lilly and Company $LLY - MarketBeat
IFM Investors Pty Ltd Boosts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Position Boosted by Parnassus Investments LLC - MarketBeat
Nuveen LLC Raises Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
The Catch Hiding In Eli Lilly Stock's Growth Story - Trefis
Eli Lilly and Company (LLY)’s Foundayo Hits New Weight Loss Milestone among Menopause Ladies - Insider Monkey
Eli Lilly Stock Outlook 2026: The Retatrutide Upgrade Cycle - EBC Financial Group
Insider Sell: Ilya Yuffa Sells 2,500 Shares of Eli Lilly and Co (LLY) - GuruFocus
Eli Lilly and Company (NYSE:LLY) Shares Up 2.2%What's Next? - MarketBeat
Eli Lilly (NYSE: LLY) EVP Ilya Yuffa sells 2,500 shares in 10b5-1 trade - Stock Titan
Abridge inks deals with Nvidia and Lilly - statnews.com
Abridge is becoming the operating system for medicine after landing Eli Lilly equity and a clinical foundation model deal with NVIDIA - Startup Fortune
Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy - Yahoo Finance
Abridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it - Fortune
Accelerating Speed to Patient: A Conversation With Eli Lilly’s Sarah O’Keeffe - PharmExec.com
Abridge picks up strategic investment from Eli Lilly, expands payer, research workflows - Fierce Healthcare
Eli Lilly (LLY) Faces Coverage Challenges for GLP-1 Weight Loss Drugs - GuruFocus
Eli Lilly (LLY) Stock Climbs on Explosive Weight Loss Drug Demand and 56% Sales Growth - FXLeaders
AlzeCure inks Alzheimer's deal with Eli Lilly - BioXconomy
Eli Lilly & Co (NYSE:LLY): An Affordable Growth Opportunity in the Pharmaceutical Sector - ChartMill
Saturna Capital Corp Sells 28,164 Shares of Eli Lilly and Company $LLY - MarketBeat
Sharpepoint LLC Makes New Investment in Eli Lilly and Company $LLY - MarketBeat
Dorsey & Whitney Trust CO LLC Sells 4,020 Shares of Eli Lilly and Company $LLY - MarketBeat
FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story - Yahoo Finance
Eli Lilly stock (US5324571083): Latest catalyst in focus - AD HOC NEWS
Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement - Pharmaceutical Technology
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis - BioWorld News
[144] ELI LILLY & Co SEC Filing - Stock Titan
Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care - Yahoo! Finance Canada
Eli Lilly stock (US5324571083): Alzheimer’s deal and obesity boom keep momentum in focus - AD HOC NEWS
Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon - Reuters
AlzeCure Enters $1 Billion Collaboration and Out-Licensing Agreement with Eli Lilly - PharmExec.com
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,300 to $1,500 - 富途牛牛
Eli Lilly (LLY) Secures FDA Approval for Ebglyss Eczema Therapy Dosing - GuruFocus
Eli Lilly Obesity Drug Market Dominance 2026: Retatrutide Trial DataNews and Statistics - IndexBox
Eli Lilly's Foundayo Tops Oral Semaglutide On Key Measures In Type 2 Diabetes Trial - NDTV Profit
Marks Group Wealth Management Inc Raises Stake in Eli Lilly and Company $LLY - MarketBeat
LLY News | ELI LILLY & CO (NYSE:LLY) - ChartMill
Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence - BioSpace
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.07%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):